Praxis Precision Medicines, Inc. PRAX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s EPS (diluted)?
- Praxis Precision Medicines, Inc. (PRAX) reported EPS (diluted) of -$3.20 in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s EPS (diluted) changed year-over-year?
- Praxis Precision Medicines, Inc.'s EPS (diluted) increased by 2.7% year-over-year, from -$3.29 to -$3.20.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s EPS (diluted) has grown at a 36.2% compound annual growth rate (CAGR), from -$3.92 to -$13.47.
- What does EPS (diluted) mean?
- The profit per share assuming all potential shares that could be created are issued.
- How do you interpret EPS (diluted)?
- A significant gap between basic and diluted EPS indicates a high potential for shareholder dilution.
- How does EPS (diluted) compare across companies?
- Used by investors to assess the impact of equity-based compensation and convertible instruments on ownership.